Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004).
Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M; Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society. Nishizawa Y, et al. Among authors: nakamura t. J Bone Miner Metab. 2005;23(2):97-104. doi: 10.1007/s00774-004-0547-6. J Bone Miner Metab. 2005. PMID: 15750686 No abstract available.
A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial.
Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, Hayashi Y, Fukunaga M, Shiraki M, Nakamura T. Matsumoto T, et al. Among authors: nakamura t. J Clin Endocrinol Metab. 2005 Sep;90(9):5031-6. doi: 10.1210/jc.2004-2552. Epub 2005 Jun 21. J Clin Endocrinol Metab. 2005. PMID: 15972580 Clinical Trial.
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study.
Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T. Uchida S, et al. Among authors: nakamura t. J Bone Miner Metab. 2005;23(5):382-8. doi: 10.1007/s00774-005-0616-5. J Bone Miner Metab. 2005. PMID: 16133688 Clinical Trial.
The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria: prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteoporosis (A-TOP) Research Group.
Shiraki M, Kuroda T, Nakamura T, Fukunaga M, Hosoi T, Orimo H, Makino K; Adequate Treatment of Osteoporosis (A-TOP) Research Group. Shiraki M, et al. Among authors: nakamura t. J Bone Miner Metab. 2006;24(3):219-25. doi: 10.1007/s00774-005-0675-7. J Bone Miner Metab. 2006. PMID: 16622735
Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y; Risedronate Phase III Research Group. Kishimoto H, et al. Among authors: nakamura t. J Bone Miner Metab. 2006;24(5):405-13. doi: 10.1007/s00774-006-0706-z. J Bone Miner Metab. 2006. PMID: 16937274 Clinical Trial.
17,324 results
You have reached the last available page of results. Please see the User Guide for more information.